Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)

Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Our compound PBF-680 is a first-in-class therapy with disease modifying effects in respiratory diseases like COPD. Over 65M patients suffer from COPD, yet there are no approved therapies that target disease progression.

PBF-680 is a unique molecule designed to specifically antagonise the Adenosine 1 Receptor (A1R). it has shown to be safe and well-tolerated in phase 1 trials and demonstrated to reduce pulmonary symptoms and inflammation in mild-to-moderate asthmatics in phase 2 trials.

With funding from the EIC Accelerator, we will demonstrate efficacy in a phase 2 trial in COPD, a market with high unmet medical need.

Proven clinical efficacy will be the major milestone to raise €30M (incl €15M EIC Equity) for a phase 3 trial, followed by an additional fund raising or IPO to independently reach market launch with PBF-680.